Cargando…
Pri-miR-124 rs531564 polymorphism and colorectal cancer risk
MiR-124 functions as a tumor suppressor and plays an important role in tumorigenesis. A common polymorphism (rs531564, C>G) in the pri-miR-124 has been recently studied in connection with cancer risk. The aim of the present study was to investigate the association between pri-miR-124 rs531564 pol...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4589757/ https://www.ncbi.nlm.nih.gov/pubmed/26423518 http://dx.doi.org/10.1038/srep14818 |
_version_ | 1782392843171528704 |
---|---|
author | Gao, Xue-ren Wang, Hui-ping Zhang, Shu-long Wang, Ming-xi Zhu, Zhan-sheng |
author_facet | Gao, Xue-ren Wang, Hui-ping Zhang, Shu-long Wang, Ming-xi Zhu, Zhan-sheng |
author_sort | Gao, Xue-ren |
collection | PubMed |
description | MiR-124 functions as a tumor suppressor and plays an important role in tumorigenesis. A common polymorphism (rs531564, C>G) in the pri-miR-124 has been recently studied in connection with cancer risk. The aim of the present study was to investigate the association between pri-miR-124 rs531564 polymorphism and the risk and clinicopathological characteristics of colorectal cancer (CRC). Two case-control studies involving 900 CRC patients and 1110 cancer-free controls showed that pri-miR-124 rs531564 polymorphism was significantly associated with the decreased risk of CRC in Xuzhou population [GG vs. CC: OR = 0.25, 95%CI = 0.09–0.67, P = 0.003; (CG+GG) vs. CC: OR = 0.73, 95%CI = 0.56–0.94, P = 0.01; GG vs. (CC+CG): OR = 0.27, 95%CI = 0.10–0.70, P = 0.004; G vs. C: OR = 0.70, 95%CI = 0.56–0.89, P = 0.003], Bengbu population [GG vs. CC: OR = 0.20, 95%CI = 0.04–0.90, P = 0.02; GG vs. (CC+CG): OR = 0.21, 95%CI = 0.05–0.95, P = 0.03; G vs. C: OR = 0.72, 95%CI = 0.54–0.98, P = 0.03] and pooled population [GG vs. CC: OR = 0.26, 95%CI = 0.11–0.59, P<0.001; (CG+GG) vs. CC: OR = 0.76, 95%CI = 0.62–0.93, P = 0.008; GG vs. (CC+CG): OR = 0.27, 95%CI = 0.12–0.62, P < 0.001; G vs. C: OR = 0.71, 95%CI = 0.59–0.85, P<0.001]. Additionally, pri-miR-124 rs531564 polymorphism was significantly associated with the decreased risk of poor differentiation and lymph node metastasis of CRC. Our results suggest that pri-miR-124 rs531564 polymorphism may be a genetic modifier for developing CRC. However, further studies are needed to validate our findings. |
format | Online Article Text |
id | pubmed-4589757 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-45897572015-10-13 Pri-miR-124 rs531564 polymorphism and colorectal cancer risk Gao, Xue-ren Wang, Hui-ping Zhang, Shu-long Wang, Ming-xi Zhu, Zhan-sheng Sci Rep Article MiR-124 functions as a tumor suppressor and plays an important role in tumorigenesis. A common polymorphism (rs531564, C>G) in the pri-miR-124 has been recently studied in connection with cancer risk. The aim of the present study was to investigate the association between pri-miR-124 rs531564 polymorphism and the risk and clinicopathological characteristics of colorectal cancer (CRC). Two case-control studies involving 900 CRC patients and 1110 cancer-free controls showed that pri-miR-124 rs531564 polymorphism was significantly associated with the decreased risk of CRC in Xuzhou population [GG vs. CC: OR = 0.25, 95%CI = 0.09–0.67, P = 0.003; (CG+GG) vs. CC: OR = 0.73, 95%CI = 0.56–0.94, P = 0.01; GG vs. (CC+CG): OR = 0.27, 95%CI = 0.10–0.70, P = 0.004; G vs. C: OR = 0.70, 95%CI = 0.56–0.89, P = 0.003], Bengbu population [GG vs. CC: OR = 0.20, 95%CI = 0.04–0.90, P = 0.02; GG vs. (CC+CG): OR = 0.21, 95%CI = 0.05–0.95, P = 0.03; G vs. C: OR = 0.72, 95%CI = 0.54–0.98, P = 0.03] and pooled population [GG vs. CC: OR = 0.26, 95%CI = 0.11–0.59, P<0.001; (CG+GG) vs. CC: OR = 0.76, 95%CI = 0.62–0.93, P = 0.008; GG vs. (CC+CG): OR = 0.27, 95%CI = 0.12–0.62, P < 0.001; G vs. C: OR = 0.71, 95%CI = 0.59–0.85, P<0.001]. Additionally, pri-miR-124 rs531564 polymorphism was significantly associated with the decreased risk of poor differentiation and lymph node metastasis of CRC. Our results suggest that pri-miR-124 rs531564 polymorphism may be a genetic modifier for developing CRC. However, further studies are needed to validate our findings. Nature Publishing Group 2015-10-01 /pmc/articles/PMC4589757/ /pubmed/26423518 http://dx.doi.org/10.1038/srep14818 Text en Copyright © 2015, Macmillan Publishers Limited http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Article Gao, Xue-ren Wang, Hui-ping Zhang, Shu-long Wang, Ming-xi Zhu, Zhan-sheng Pri-miR-124 rs531564 polymorphism and colorectal cancer risk |
title | Pri-miR-124 rs531564 polymorphism and colorectal cancer risk |
title_full | Pri-miR-124 rs531564 polymorphism and colorectal cancer risk |
title_fullStr | Pri-miR-124 rs531564 polymorphism and colorectal cancer risk |
title_full_unstemmed | Pri-miR-124 rs531564 polymorphism and colorectal cancer risk |
title_short | Pri-miR-124 rs531564 polymorphism and colorectal cancer risk |
title_sort | pri-mir-124 rs531564 polymorphism and colorectal cancer risk |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4589757/ https://www.ncbi.nlm.nih.gov/pubmed/26423518 http://dx.doi.org/10.1038/srep14818 |
work_keys_str_mv | AT gaoxueren primir124rs531564polymorphismandcolorectalcancerrisk AT wanghuiping primir124rs531564polymorphismandcolorectalcancerrisk AT zhangshulong primir124rs531564polymorphismandcolorectalcancerrisk AT wangmingxi primir124rs531564polymorphismandcolorectalcancerrisk AT zhuzhansheng primir124rs531564polymorphismandcolorectalcancerrisk |